Erasmus University Medical Center Partners With Complete Genomics to Begin Developing Its Genomic Medicine Pipeline
May 19 2011 - 8:00AM
Complete Genomics Inc. (Nasdaq:GNOM), a complete human genome
sequencing company that has developed and commercialized an
innovative DNA sequencing platform, announced today an expansion of
its collaboration with Erasmus University Medical Center (Erasmus
MC), based in Rotterdam, the Netherlands. This agreement calls for
Complete Genomics to sequence 250 DNA samples for Erasmus MC
research studies over the next 12 months. Samples will come from
patients with leukemia and other cancers and congenital
malformations, such as craniosynostosis. Erasmus MC is working with
external collaborators, including Sanquin Blood Supply Foundation,
a not-for-profit organization that manages the blood supply in the
Netherlands, and various teams at the Academic Medical Center of
the University of Amsterdam to obtain some of the samples.
Erasmus MC and Complete Genomics are also
collaborating in several other research areas, which have not yet
been disclosed. As part of the agreement, Erasmus MC is also
allowing Complete Genomics to use its bioinformatics training
center for customer training purposes. That center is ideally
located in the center of Europe.
"We decided to focus our research efforts with
Complete Genomics on diseases where the current technology has not
been able to identify the genetic variants responsible," said
Professor Dr. Peter J. van der Spek, head of bioinformatics at
Erasmus MC. "Its complete human genome sequencing service will
allow us to study genetic variations at a higher resolution and
greater sensitivity than has been previously possible. We are
optimistic that we will be able to obtain answers to some of the
scientific questions that have proven elusive to date."
Dr. Clifford Reid, chairman, president and CEO of
Complete Genomics, added, "By using our complete human genome
sequencing service, Erasmus MC will be able to obtain timely,
high-quality data to further its research efforts without having to
maintain and update sequencing instruments of its own. We hope that
by furthering its understanding of the genetics of these complex
diseases, Erasmus MC can be at the forefront of developing better
diagnostic screens that form the basis for genetic testing in
monogenetic diseases and targeted treatment development for
diseases such as cancer."
"Since only 4 percent of the Dutch national
healthcare budget is currently spent on diagnostics and yet 72
percent of medical decisions depend on those diagnostics, we expect
this new technology to change the way patient stratification is
conducted for targeted treatments in the very near future in the
Netherlands," van der Spek added.
Additional expertise in technology and data
management is being co-developed for this translational medicine
project through strategic partnerships with companies such as
Ingenuity, Biobase, TIBCO/Spotfire, Oracle and VX Company.
About Complete Genomics
Complete Genomics is a complete human genome
sequencing company that has developed and commercialized an
innovative DNA sequencing platform. The Complete Genomics Analysis
Platform (CGA™ Platform) combines Complete Genomics' proprietary
human genome sequencing technology with our advanced informatics
and data management software. We offer this solution as an
innovative, end-to-end, outsourced service, CGA™ Service, and
provide customers with data that is immediately ready to be used
for genome-based research. Additional information can be found at
http://www.completegenomics.com.
The Complete Genomics logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8216
About Erasmus University Medical Center
Rotterdam Erasmus MC is the largest and one of the most
authoritative scientific University Medical Centers in Europe. More
then 13,000 staff members work within the core tasks of patient
care, education, and scientific research on the continuous
improvement and enforcement of individual patient care and social
healthcare. They develop high-level knowledge, pass this on to
future professionals, and apply it in everyday patient care.
Erasmus MC is part of the Dutch Federation of University Medical
Centers (NFU). See www.nfu.nl and www.erasmusmc.nl
Forward-Looking Statements
Certain statements in this press release, including statements
relating to the ability of our customers to use the genome
sequencing data that we provide to them to develop better
diagnostic tools and targeted therapies for diseases and to change
the way patient stratification is conducted for targeted disease
treatments are forward-looking statements that are subject to risks
and uncertainties. Readers are cautioned that these forward-looking
statements are based on management's current expectations, and
actual results may differ materially from those projected. The
following factors, without limitation, could cause actual results
to differ materially from those in the forward-looking
statements: the usefulness of genomic data in identifying or
treating disease; the ability of our customers to successfully
analyze the genomic data we provide; and the ability of researchers
to convert genomic data into medically valuable
information. More information on potential factors that could
affect the usefulness of the genomic data that we provide to our
customers is included in our Securities and Exchange Commission
filings and reports, including the risks identified under the
section captioned "Risk Factors" in our Registration Statement on
Form S-1 filed on May 18, 2010. We disclaim any obligation to
update information contained in these forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACT: Complete Genomics Inc.
Jennifer Turcotte
Vice President of Marketing
(650) 943-2846
jturcotte@completegenomics.com
Waggener Edstrom Worldwide
Healthcare
Lisa Osborne
Account Director
(202) 261-7806
completegenomics@waggeneredstrom.com
Global X Genomics and Bi... (NASDAQ:GNOM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Global X Genomics and Bi... (NASDAQ:GNOM)
Historical Stock Chart
From Jul 2023 to Jul 2024